Big pharma to close 26 more plants

Well, big pharma doesn't appear to be the safe haven for investors or employees these days. The Industrial Info Resources' Pharmaceutical Tracker has revealed that there are at least 26 plants poised for shutdown. This is in addition to those J&J, Pfizer and Schering-Plough and other layoffs we keep hearing about, and employees in pharmaceutical advertising and marketing might take the biggest hit. 

Why the slump? The combination of a down economy coupled with patent expirations, negative press about popular medications, fewer prescriptions being filled and some FDA difficulties might be to blame. Continued rumors about layoffs and plant closures are unlikely to help much, either.

- read the report
- get the story in BusinessWeek
- see more at Market Watch
- here's World of DTC Marketing's take

Relate dArticles:
Fortune snubs Big Pharma in employers list
Top 8 layoffs of 2007
Pharma layoffs set new record

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.